2022 ICD-10-CM Diagnosis Code C51

Malignant neoplasm of vulva

    2016 2017 2018 2019 2020 2021 2022 Non-Billable/Non-Specific Code
  • C51 should not be used for reimbursement purposes as there are multiple codes below it that contain a greater level of detail.
  • The 2022 edition of ICD-10-CM C51 became effective on October 1, 2021.
  • This is the American ICD-10-CM version of C51 - other international versions of ICD-10 C51 may differ.
Type 1 Excludes
Type 1 Excludes Help
A type 1 excludes note is a pure excludes. It means "not coded here". A type 1 excludes note indicates that the code excluded should never be used at the same time as C51. A type 1 excludes note is for used for when two conditions cannot occur together, such as a congenital form versus an acquired form of the same condition.
  • carcinoma in situ of vulva (
    ICD-10-CM Diagnosis Code D07.1

    Carcinoma in situ of vulva

      2016 2017 2018 2019 2020 2021 2022 Billable/Specific Code
    Applicable To
    • Severe dysplasia of vulva
    • Vulvar intraepithelial neoplasia III [VIN III]
    Type 1 Excludes
    • moderate dysplasia of vulva (N90.1)
    • vulvar intraepithelial neoplasia II [VIN II] (N90.1)
    D07.1
    )
The following code(s) above C51 contain annotation back-references
Annotation Back-References
In this context, annotation back-references refer to codes that contain:
  • Applicable To annotations, or
  • Code Also annotations, or
  • Code First annotations, or
  • Excludes1 annotations, or
  • Excludes2 annotations, or
  • Includes annotations, or
  • Note annotations, or
  • Use Additional annotations
that may be applicable to C51:
  • C00-D49
    2022 ICD-10-CM Range C00-D49

    Neoplasms

    Note
    • Functional activity
    • All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
    • Morphology [Histology]
    • Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
    • Primary malignant neoplasms overlapping site boundaries
    • A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
    • Malignant neoplasm of ectopic tissue
    • Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).
    Neoplasms
  • C51-C58
    2022 ICD-10-CM Range C51-C58

    Malignant neoplasms of female genital organs

    Includes
    • malignant neoplasm of skin of female genital organs
    Malignant neoplasms of female genital organs
Clinical Information
  • Primary or metastatic malignant neoplasm involving the vulva.
  • Vulvar cancer is a rare type of cancer. It forms in a woman's external genitals, called the vulva. The cancer usually develops slowly over several years. First, precancerous cells grow on vulvar skin. This is called vulvar intraepithelial neoplasia (vin), or dysplasia. Not all vin cases turn into cancer, but it is best to treat it early. Often, vulvar cancer doesn't cause early symptoms. However, see your doctor for testing if you notice
    • a lump in the vulva
    • vulvar itching or tenderness
    • bleeding that is not your period
    being older and having a human papillomavirus infection are risk factors for vulvar cancer. Treatment varies, depending on your overall health and how advanced the cancer is. It might include laser therapy, surgery, radiation or chemotherapy. nih: national cancer institute
Code History
  • 2016 (effective 10/1/2015): New code (first year of non-draft ICD-10-CM)
  • 2017 (effective 10/1/2016): No change
  • 2018 (effective 10/1/2017): No change
  • 2019 (effective 10/1/2018): No change
  • 2020 (effective 10/1/2019): No change
  • 2021 (effective 10/1/2020): No change
  • 2022 (effective 10/1/2021): No change
ICD-10-CM Codes Adjacent To C51
C50.829 Malignant neoplasm of overlapping sites of unspecified male breast
C50.9 Malignant neoplasm of breast of unspecified site
C50.91 Malignant neoplasm of breast of unspecified site, female
C50.911 Malignant neoplasm of unspecified site of right female breast
C50.912 Malignant neoplasm of unspecified site of left female breast
C50.919 Malignant neoplasm of unspecified site of unspecified female breast
C50.92 Malignant neoplasm of breast of unspecified site, male
C50.921 Malignant neoplasm of unspecified site of right male breast
C50.922 Malignant neoplasm of unspecified site of left male breast
C50.929 Malignant neoplasm of unspecified site of unspecified male breast
C51 Malignant neoplasm of vulva
C51.0 Malignant neoplasm of labium majus
C51.1 Malignant neoplasm of labium minus
C51.2 Malignant neoplasm of clitoris
C51.8 Malignant neoplasm of overlapping sites of vulva
C51.9 Malignant neoplasm of vulva, unspecified
C52 Malignant neoplasm of vagina
C53 Malignant neoplasm of cervix uteri
C53.0 Malignant neoplasm of endocervix
C53.1 Malignant neoplasm of exocervix
C53.8 Malignant neoplasm of overlapping sites of cervix uteri

Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.